N-terminal truncated metabolite of glucagon-like peptide GLP-1-(7-36)
(Cat. No. 2082) formed by dipeptidyl peptidase-IV cleavage. Acts as an antagonist at the human GLP-1 receptor. Inhibits hepatic glucose production in vivo
and is a weak insulinotropic agent.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor.
Knudsen and Pridal
GLP-1 (9-36) amide, cleavage product of GLP-1 (7-36) amide is a glucoregulatory peptide.
Elahi et al.
Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo.
Deacon et al.